Cosmo Pharmaceuticals' Clascoterone Shows Promising Results in Hair Loss Treatment

Cosmo Pharmaceuticals announced on April 15, 2026, that its experimental hair loss treatment, clascoterone, demonstrated sustained hair growth and long-term safety in men suffering from common pattern baldness after a year of use. This announcement follows a year-long extension study that builds on late-stage data released in December 2025, where clascoterone met its primary objectives in two large studies involving 1,465 men over six months.

UsNews and World ReportCosmo Pharma’s male hair loss treatment shows sustained hair growth in year-long study By Reuters

The results from the year-long study indicate that men who continued using clascoterone for 12 months experienced a statistically significant 2.39-times improvement in hair count compared to those who discontinued treatment after six months. In contrast, patients who stopped the treatment saw a notable decline in hair count, highlighting the importance of ongoing use for sustained results. Clascoterone functions as a topical solution that inhibits the effects of male hormones in the scalp, which are primarily responsible for hair follicle shrinkage and subsequent hair loss.

Cosmo Pharma’s male hair loss treatment shows sustained hair growth in year-long study By ReutersUsNews and World Report

Cosmo Pharmaceuticals reported that the safety profile of clascoterone over the 12-month period was comparable to that of a placebo, with no significant hormone-related side effects observed. This finding is crucial for potential users concerned about the safety of hair loss treatments.

Cosmo Pharma’s male hair loss treatment shows sustained hair growth in year-long study By Reuters

Cosmo Pharmaceuticals plans to seek U.S. regulatory approval for clascoterone in early 2027. The company aims to submit comprehensive data from the late-stage studies for publication at scientific meetings. Giovanni Di Napoli, CEO of Cosmo, expressed the company's intention to explore licensing options for the drug, emphasizing the goal of partnering with an entity capable of scaling the treatment to reach millions of men globally.

Cosmo Pharma’s male hair loss treatment shows sustained hair growth in year-long study By Reuters

While the results are promising, some experts in the field of dermatology urge caution. They emphasize the need for further studies to confirm long-term efficacy and safety, particularly in diverse populations. Critics also point out that while clascoterone shows potential, it is essential to compare its effectiveness against existing treatments in the market.

Cosmo Pharma’s male hair loss treatment shows sustained hair growth in year-long study By Reuters

As Cosmo Pharmaceuticals prepares for regulatory submission, the company will likely focus on solidifying partnerships for distribution and continuing to gather data on clascoterone's long-term effects. The upcoming scientific meetings will provide a platform for sharing findings and engaging with the broader medical community.

Cosmo Pharma’s male hair loss treatment shows sustained hair growth in year-long study By Reuters

“39-times improvementin hair count compared to those who stopped the treatment aftersix months.” — Cosmo Pharmaceuticals

Cosmo Pharma’s male hair loss treatment shows sustained hair growth in year-long study By Reuters

“We want to find aperfect partner that can scale this drug and can reach millionsof men globally as quickly as possible.” — Giovanni Di Napoli, CEO of Cosmo Pharmaceuticals

Cosmo Pharma’s male hair loss treatment shows sustained hair growth in year-long study By Reuters